Boston, MA, USA - Zipcode Bio, a startup focusing on next-generation nucleic acid applications, has announced that its co-founder and CEO, Dr. Jason Zhang will present a talk at the World Vaccine Congress this April 1st, in Washington D.C. As a seasoned professional in nucleic acid technologies, Dr. Zhang will present on the topic "From a preventive vaccine to a therapeutic vaccine", offering a glimpse into the future of RNA therapeutics.
Zipcode Bio leverages pioneering DNP technology to craft innovative solutions aimed at redefining the development of RNA based medicines. The presentation will provide insight into cutting-edge research and Zipcode Bio’s commitment to developing revolutionary therapeutics.
For more information about the World Vaccine Congress Washington, please visit https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
About Zipcode Bio: Zipcode Bio is a biotechnology company specializing in the development of next-generation nucleic acid applications that are accessible, widely distributable, and superior in efficacy and safety. It is co-Founded by Dr. Drew Weissman, Dr. Virgil Percec and Dr. Jason Zhang in Nov. 2023. The scientific strength is based on the co-founders’ deep knowledge in RNA medicine, breakthrough DNP technology, and focus on unmet medical needs. Zipcode Bio stands at the forefront of developing revolutionary solutions with the potential to transform patient care. Zipcode Bio has assembled a dynamic team committed to pushing scientific boundaries and developing novel therapeutics to address unmet healthcare needs. The company’s dedication to innovation, precision, and accessibility underscores its mission to improve therapeutic outcomes and contribute to the evolution of global healthcare.
For more information, please contact jason.zhang@zipcodebio.com
Boston, MA, USA – Zipcode Bio, a startup focusing on next-generation nucleic acid applications, congratulates its Co-Founder, Dr. Drew Weissman on receiving the 2023 Nobel Prize in Physiology or Medicine at the Nobel Prize Ceremony in Stockholm, Sweden. The company applauds Dr. Weissman for his exceptional contributions to mRNA technology.
Dr. Weissman has played a crucial role in shaping the company’s mission to develop innovative and cost-effective treatments. Leveraging precise genetic instructions, Zipcode Bio focuses on advancing targeted delivery solutions for nucleic acids, including mRNA and oligonucleotides, ensuring optimal therapeutic outcomes and tolerability.
“We are immensely proud of Dr. Drew Weissman for his well-deserved recognition with the 2023 Nobel Prize, acknowledging his pioneering contributions to mRNA technology. His vision and leadership have been pivotal in advancing next-generation nucleic acid applications with targeted delivery,” said Dr. Jason Zhang, Co-Founder and CEO at Zipcode Bio.
About Zipcode Bio: Zipcode Bio is a biotechnology company specializing in the development of next-generation nucleic acid applications that are accessible, widely distributable, and superior in efficacy and safety. It is co-Founded by Dr. Drew Weissman, Dr. Virgil Percec and Dr. Jason Zhang in Nov. 2023. The scientific strength is based on the co-founders’ deep knowledge in RNA medicine, breakthrough DNP technology, and focus on unmet medical needs. Zipcode Bio stands at the forefront of developing revolutionary solutions with the potential to transform patient care. Zipcode Bio has assembled a dynamic team committed to pushing scientific boundaries and developing novel therapeutics to address unmet healthcare needs. The company’s dedication to innovation, precision, and accessibility underscores its mission to improve therapeutic outcomes and contribute to the evolution of global healthcare.
For more information, please contact jason.zhang@zipcodebio.com